Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cytek BiosciencesCTKB +1.24%72 Price-to-Tangible-Book is 2.19 as of Sep. 16, 2026. GuruFocus rates CTKB with a GF Score™ of 72/100 and a GF Value™ of $5.53 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 703 Medical Devices & Instruments companies, Cytek Biosciences ranks better than 57.18% on this metric.
The historical rank and industry rank for Cytek Biosciences's Price-to-Tangible-Book or its related term are showing as below:
CTKB'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.26 Med: 2.42 Max: 7.12
Current: 2.19
During the past 7 years, Cytek Biosciences's highest Price to Tangible Book Ratio was 7.12. The lowest was 1.26. And the median was 2.42.
CTKB's Price-to-Tangible-Book is ranked better than 57.18% of 703
companies
in the Medical Devices & Instruments industry
Industry Median: 2.6
vs CTKB: 2.19
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Cytek Biosciences Price-to-Tangible-Book Related Terms
Cytek Biosciences Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTKB vs KIDS, DCTH, CERS: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, Cytek Biosciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Cytek Biosciences (CTKB) has a Price-to-Tangible-Book of 2.19 as of Sep. 16, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Cytek Biosciences and its competitors. According to the industry distribution chart, Cytek Biosciences ranks #301 out of 703 companies in the Medical Devices & Instruments industry, placing it in the top 42.8%.
Is Cytek Biosciences' Price-to-Tangible-Book too high?
Cytek Biosciences' current Price-to-Tangible-Book is 2.19. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.60. Cytek Biosciences' value of 2.19 is 15.8% below this industry median. Based on the distribution chart, Cytek Biosciences ranks #301 out of 703 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Cytek Biosciences has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Price-to-Tangible-Book compare to KIDS and DCTH?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #301 out of 703 companies for Price-to-Tangible-Book. This puts Cytek Biosciences in the upper half of its industry. The industry median Price-to-Tangible-Book is 2.60. Cytek Biosciences' value of 2.19 is 15.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.60, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cytek Biosciences's current Price-to-Tangible-Book of 2.19 is 15.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Cytek Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current Price-to-Tangible-Book is 2.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.53, compared to a current price of $4.89 — trading 11.6% below its estimated fair value. The current Price-to-Tangible-Book is 2.19 and 15.8% below the Medical Devices & Instruments industry median of 2.60. Cytek Biosciences' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Price-to-Tangible-Book is 2.19 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.89 is trading 11.6% below its estimated GF Value™ of $5.53.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
Price-to-Tangible-Book: 2.19
GF Value™: $5.53 vs. price of $4.89 (11.6% below fair value)
Industry Position: 15.8% below the Medical Devices & Instruments median (#301 of 703)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
72GF Score
Get the complete analysis for CTKB
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
